QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)

Keros Therapeutics (KROS) Stock Forecast, Price & News

$30.82
-1.06 (-3.32%)
(As of 10/2/2023 ET)
Compare
Today's Range
$30.57
$33.08
50-Day Range
$31.57
$43.01
52-Week Range
$30.57
$59.96
Volume
294,439 shs
Average Volume
209,583 shs
Market Capitalization
$914.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$94.33

Keros Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
206.1% Upside
$94.33 Price Target
Short Interest
Bearish
5.60% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.84mentions of Keros Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.25) to ($5.22) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

484th out of 969 stocks

Pharmaceutical Preparations Industry

223rd out of 452 stocks


KROS stock logo

About Keros Therapeutics (NASDAQ:KROS) Stock

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical need in the United States. The company's lead protein therapeutic product candidate KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-047, a small molecule product candidate that is in Phase II clinical trials for the treatment of functional iron deficiency; and KER-012, which is in Phase II clinical trials to treat pulmonary arterial hypertension and cardiovascular disorders. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

KROS Price History

KROS Stock News Headlines

Wedbush Sticks to Their Buy Rating for Keros Therapeutics (KROS)
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"
The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>
Truist Financial Remains a Buy on Keros Therapeutics (KROS)
Wedbush Sticks to Its Buy Rating for Keros Therapeutics (KROS)
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"
The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>
Wedbush Initiates a Buy Rating on Keros Therapeutics (KROS)
Where Keros Therapeutics Stands With Analysts
Keros Therapeutics (NASDAQ: KROS)
H.C. Wainwright Remains a Buy on Keros Therapeutics (KROS)
Keros Therapeutics GAAP EPS of -$1.26
See More Headlines
Receive KROS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KROS Company Calendar

Last Earnings
8/07/2023
Today
10/02/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KROS
Fax
N/A
Employees
121
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$94.33
High Stock Price Forecast
$110.00
Low Stock Price Forecast
$65.00
Forecasted Upside/Downside
+206.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-104,680,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$20.10 million
Book Value
$10.07 per share

Miscellaneous

Free Float
21,357,000
Market Cap
$914.12 million
Optionable
Not Optionable
Beta
1.16
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Jasbir S. Seehra Ph.D. (Age 67)
    Pres, CEO, Treasurer, & Director
    Comp: $985.58k
  • Mr. Christopher Rovaldi M.Sc. (Age 49)
    Chief Operating Officer
    Comp: $708.75k
  • Dr. Simon Cooper MBBS (Age 53)
    Chief Medical Officer
    Comp: $654.27k
  • Mr. Keith C. Regnante MBA (Age 53)
    Chief Financial Officer
  • Ms. Esther Cho J.D.
    Sr. VP, Gen. Counsel & Sec.
  • Ms. Robin Wagner
    VP of HR
  • Dr. Jennifer Lachey Ph.D. (Age 50)
    Sr. VP of Discovery
  • Mr. John Oram M.B.A.
    Sr. VP of Program & Portfolio Management













KROS Stock - Frequently Asked Questions

Should I buy or sell Keros Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Keros Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KROS shares.
View KROS analyst ratings
or view top-rated stocks.

What is Keros Therapeutics' stock price forecast for 2023?

7 Wall Street analysts have issued 1 year target prices for Keros Therapeutics' stock. Their KROS share price forecasts range from $65.00 to $110.00. On average, they expect the company's share price to reach $94.33 in the next year. This suggests a possible upside of 206.1% from the stock's current price.
View analysts price targets for KROS
or view top-rated stocks among Wall Street analysts.

How have KROS shares performed in 2023?

Keros Therapeutics' stock was trading at $48.02 on January 1st, 2023. Since then, KROS stock has decreased by 35.8% and is now trading at $30.82.
View the best growth stocks for 2023 here
.

When is Keros Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our KROS earnings forecast
.

How were Keros Therapeutics' earnings last quarter?

Keros Therapeutics, Inc. (NASDAQ:KROS) announced its earnings results on Monday, August, 7th. The company reported ($1.27) EPS for the quarter, beating analysts' consensus estimates of ($1.34) by $0.07. During the same quarter in the prior year, the business posted ($1.13) earnings per share.

What ETFs hold Keros Therapeutics' stock?

ETFs with the largest weight of Keros Therapeutics (NASDAQ:KROS) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) and ALPS Medical Breakthroughs ETF (SBIO).BNY Mellon Innovators ETF (BKIV).

What other stocks do shareholders of Keros Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Keros Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Cloudera (CLDR), CVS Health (CVS), Inovio Pharmaceuticals (INO), Iovance Biotherapeutics (IOVA), Karyopharm Therapeutics (KPTI), Neurocrine Biosciences (NBIX), Novavax (NVAX) and Pfizer (PFE).

When did Keros Therapeutics IPO?

(KROS) raised $75 million in an initial public offering (IPO) on Wednesday, April 8th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

What is Keros Therapeutics' stock symbol?

Keros Therapeutics trades on the NASDAQ under the ticker symbol "KROS."

How do I buy shares of Keros Therapeutics?

Shares of KROS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Keros Therapeutics' stock price today?

One share of KROS stock can currently be purchased for approximately $30.82.

How much money does Keros Therapeutics make?

Keros Therapeutics (NASDAQ:KROS) has a market capitalization of $914.12 million and generates $20.10 million in revenue each year. The company earns $-104,680,000.00 in net income (profit) each year or ($4.54) on an earnings per share basis.

How many employees does Keros Therapeutics have?

The company employs 121 workers across the globe.

How can I contact Keros Therapeutics?

Keros Therapeutics' mailing address is 99 HAYDEN AVENUE SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER, LEXINGTON MA, 02421. The official website for the company is www.kerostx.com. The company can be reached via phone at 617-314-6297 or via email at jbalanova@troutgroup.com.

This page (NASDAQ:KROS) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -